RESUMO
ETHNOPHARMACOLOGICAL RELEVANCE: Kuanxiong aerosol has been reported to be an effective and safe clinical treatment for angina pectoris (AP). AIM OF THE STUDY: To explore the potential pharmacological mechanism of Kuanxiong aerosol by combined methods of network pharmacology prediction and experimental verification. MATERIALS AND METHODS: Networks of Kuanxiong aerosol-associated targets and AP-related genes were constructed through STRING database. Potential targets and pathway enrichment analysis related to the therapeutic efficacy of Kuanxiong aerosol were identified using Cytoscape and Database for Annotation, Visualization and Integrated Discovery (DAVID). To explore the mechanism of action of Kuanxiong aerosol, its in vitro effects on myocardial hypoxia, inflammatory cytokines, and oxidative injury, and its in vivo pharmacological effects on myocardial ischemia and cardiac fibrosis were studied in rat models. RESULTS: Network pharmacology analysis revealed that the potential targets mainly include the Fas ligand (FASLG), interleukin 4 (IL4), and catalase (CAT), which mediated the processes of apoptosis, and cellular responses to hypoxia, lipopolysaccharide (LPS), reactive oxygen species (ROS), and mechanical stimulus. Multiple pathways, such as the hypoxia-inducible factor 1 (HIF1) and tumor necrosis factor (TNF) pathways were found to be closely related to the pharmacological protective mechanism of Kuanxiong aerosol against AP. In addition, Kuanxiong aerosol suppressed the hypoxia, LPS, and hydrogen peroxide (H2O2)-induced injuries of H9c2 cardiomyocytes through the regulation of HIF1A, suppressed expression of IL6 and TNF, and antioxidant property. In the rat model of myocardial ischemia, Kuanxiong aerosol was found to lower the creatine kinase (CK), creatine kinase-myocardial band (CK-MB), and lactate dehydrogenase (LDH) levels, without altering the hemodynamic function. Kuanxiong aerosol was capable of attenuating cardiac fibrosis and improving cardiac function in a cardiac fibrosis rat model. CONCLUSIONS: This study revealed that the pharmacological mechanisms of Kuanxiong aerosol for AP therapy were related to anti-myocardial ischemia, anti-inflammation, and anti-oxidation via a non-hemodynamic manner, indicating that Kuanxiong aerosol is a preferable drug clinically for AP treatment due to its both preventive and protective effects.
Assuntos
Angina Pectoris/tratamento farmacológico , Fármacos Cardiovasculares/farmacologia , Miócitos Cardíacos/efeitos dos fármacos , Óleos Voláteis/farmacologia , Biologia de Sistemas , Administração Sublingual , Aerossóis , Angina Pectoris/genética , Angina Pectoris/metabolismo , Angina Pectoris/patologia , Animais , Fármacos Cardiovasculares/administração & dosagem , Linhagem Celular , Bases de Dados Genéticas , Modelos Animais de Doenças , Combinação de Medicamentos , Regulação da Expressão Gênica , Redes Reguladoras de Genes , Masculino , Miócitos Cardíacos/metabolismo , Miócitos Cardíacos/patologia , Óleos Voláteis/administração & dosagem , Mapas de Interação de Proteínas , Ratos Wistar , Transdução de SinaisRESUMO
BACKGROUND: Although we and others have reported cases of patients with Anderson-Fabry disease (AFD) complicated by coronary spastic angina (CSA), the prevalence of CSA in these patients remains unknown. MethodsâandâResults: We performed the acetylcholine-induced provocation test, according to the Japanese guidelines for the diagnosis and treatment of patients with CSA, in 9 consecutive patients having 5 independent AFD pedigrees. Coronary spasms were provoked in conjunction with symptoms and ECG ischemic changes in 8 of 9 (89%) patients with AFD. CONCLUSIONS: We found an unexpectedly high prevalence of CSA in patients with AFD.
Assuntos
Angina Pectoris/etiologia , Vasoespasmo Coronário/etiologia , Doença de Fabry/complicações , Acetilcolina/farmacologia , Adulto , Idoso , Angina Pectoris/patologia , Angiografia Coronária , Vasoespasmo Coronário/patologia , Eletrocardiografia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Isquemia Miocárdica/etiologia , PrevalênciaRESUMO
BACKGROUND: Cell therapy with bone marrow (BM)-derived progenitors has emerged as a promising therapeutic for refractory angina (RA) patients. In the present study, we evaluated the safety and preliminary efficacy of transcatheter delivery of autologous BM-derived advanced therapy medicinal product CD133+ cells (ATMP-CD133) in RA patients, correlating perfusion outcome with cell function. METHODS: In the phase I "Endocavitary Injection of Bone Marrow Derived CD133+ Cells in Ischemic Refractory Cardiomyopathy" (RECARDIO) trial, a total of 10 patients with left ventricular (LV) dysfunction (ejection fraction ≤ 45%) and evidence of reversible ischemia, as assessed by single-photon emission computed tomography (SPECT), underwent BM aspiration and fluoroscopy-based percutaneous endomyocardial delivery of ATMP-CD133. Patients were evaluated at 6 and 12 months for safety and preliminary efficacy endpoints. ATMP-CD133 samples were used for in vitro correlations. RESULTS: Patients were treated safely with a mean number of 6.57 ± 3.45 × 106 ATMP-CD133. At 6-month follow-up, myocardial perfusion at SPECT was significantly ameliorated in terms of changes in summed stress (from 18.2 ± 8.6 to 13.8 ± 7.8, p = 0.05) and difference scores (from 12.0 ± 5.3 to 6.1 ± 4.0, p = 0.02) and number of segments with inducible ischemia (from 7.3 ± 2.2 to 4.0 ± 2.7, p = 0.003). Similarly, Canadian Cardiovascular Society and New York Heart Association classes significantly improved at follow-up vs baseline (p ≤ 0.001 and p = 0.007, respectively). Changes in summed stress score changes positively correlated with ATMP-CD133 release of proangiogenic cytokines HGF and PDGF-bb (r = 0.80, p = 0.009 and r = 0.77, p = 0.01, respectively) and negatively with the proinflammatory cytokines RANTES (r = - 0.79, p = 0.01) and IL-6 (r = - 0.76, p = 0.02). CONCLUSION: Results of the RECARDIO trial suggested safety and efficacy in terms of clinical and perfusion outcomes in patients with RA and LV dysfunction. The observed link between myocardial perfusion improvements and ATMP-CD133 secretome may represent a proof of concept for further mechanistic investigations. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02059681 . Registered 11 February 2014.
Assuntos
Angina Pectoris/terapia , Transplante de Medula Óssea/métodos , Cardiomiopatias/terapia , Isquemia Miocárdica/terapia , Intervenção Coronária Percutânea/métodos , Disfunção Ventricular Esquerda/terapia , Antígeno AC133/genética , Antígeno AC133/metabolismo , Idoso , Angina Pectoris/diagnóstico por imagem , Angina Pectoris/genética , Angina Pectoris/patologia , Becaplermina/genética , Becaplermina/metabolismo , Células da Medula Óssea/citologia , Células da Medula Óssea/metabolismo , Cardiomiopatias/diagnóstico por imagem , Cardiomiopatias/genética , Cardiomiopatias/patologia , Quimiocina CCL5/genética , Quimiocina CCL5/metabolismo , Endocárdio , Expressão Gênica , Fator de Crescimento de Hepatócito/genética , Fator de Crescimento de Hepatócito/metabolismo , Humanos , Interleucina-6/genética , Interleucina-6/metabolismo , Masculino , Isquemia Miocárdica/diagnóstico por imagem , Isquemia Miocárdica/genética , Isquemia Miocárdica/patologia , Segurança do Paciente , Estudos Prospectivos , Tomografia Computadorizada de Emissão de Fóton Único , Transplante Autólogo , Resultado do Tratamento , Disfunção Ventricular Esquerda/diagnóstico por imagem , Disfunção Ventricular Esquerda/genética , Disfunção Ventricular Esquerda/patologiaRESUMO
BACKGROUND: A recent study showed that coronary high-intensity plaques (HIPs) visualized by noncontrast T1-weighted imaging (T1WI) in cardiac magnetic resonance were associated with coronary events. We used coronary angioscopy to analyze HIP plaque morphology. METHODS AND RESULTS: A total 17 lesions from 17 patients with stable or unstable angina pectoris were evaluated at the culprit lesion by noncontrast T1WI using 1.5-T magnetic resonance; of them, nine (53%) were HIPs and eight (47%) were non-HIPs, and all were analyzed by coronary angioscopy. We assessed the existence of thrombus and plaque yellow color grade (YG). YG was assessed visually according to a four-grade scale: 0, white; 1, light yellow; 2, yellow; 3, intense yellow. The frequency of thrombus was significantly higher in HIPs than in non-HIPs (89% vs. 25%, respectively; p=0.007). YG was significantly more frequent in HIPs than in non-HIPs (2.2±0.4 vs. 0.7±0.7, respectively; p=0.01). CONCLUSIONS: These data indicated that HIPs on noncontrast T1WI were associated with the presence of high-grade yellow plaque with thrombus.
Assuntos
Angina Pectoris/diagnóstico por imagem , Vasos Coronários/diagnóstico por imagem , Placa Aterosclerótica/diagnóstico por imagem , Trombose/diagnóstico por imagem , Idoso , Idoso de 80 Anos ou mais , Angina Pectoris/patologia , Angioscopia , Vasos Coronários/patologia , Feminino , Humanos , Imageamento por Ressonância Magnética , Masculino , Pessoa de Meia-Idade , Placa Aterosclerótica/patologia , Trombose/patologiaRESUMO
Objectives. To investigate the potential association of a set of serum cytokines with the severity of coronary artery disease (CAD). Methods. A total of 201 patients who underwent coronary angiography for chest discomfort were enrolled. The concentrations of serum IFN-γ, TNF-α, IL-2, IL-4, IL-6, IL-10, IL-9, and IL-17 were determined by xMAP multiplex technology. The CAD severity was assessed by Gensini score (GS). Results. The serum levels of TNF-α, IL-6, IL-9, IL-10, and IL-17 were significantly higher in high GS group (GS ≥ 38.5) than those in low GS group (GS < 38.5). Positive correlations were also found between these cytokines and the severity of CAD. After adjustment for other associated factors, three serum cytokines (IL-6, IL-9, and IL-17) and two clinical risk factors (creatinine and LDL-C) were identified as the independent predictors of increased severity of CAD. ROC curve analysis revealed that the logistic regression risk prediction model had a good performance on predicting CAD severity. Conclusions. Combinatorial analysis of serum cytokines (IL-6, IL-9, and IL-17) with clinical risk factors (creatinine and LDL-C) may contribute to the evaluation of the severity of CAD and may help guide the risk stratification of angina patients, especially in primary health facilities and in the catheter lab resource-limited settings.
Assuntos
Angina Pectoris/sangue , Doença da Artéria Coronariana/sangue , Doença da Artéria Coronariana/diagnóstico por imagem , Citocinas/sangue , Idoso , Angina Pectoris/patologia , LDL-Colesterol/sangue , Angiografia Coronária , Doença da Artéria Coronariana/patologia , Creatinina/sangue , Feminino , Humanos , Interleucina-17/sangue , Interleucina-6/sangue , Interleucina-9/sangue , Masculino , Pessoa de Meia-Idade , Fatores de Risco , Índice de Gravidade de DoençaRESUMO
BACKGROUND: Even in absence of obstructive coronary artery disease women with angina pectoris have a poor prognosis possibly due to coronary microvascular disease. Coronary microvascular disease can be assessed by transthoracic Doppler echocardiography measuring coronary flow velocity reserve (CFVR) and by positron emission tomography measuring myocardial blood flow reserve (MBFR). Diffuse myocardial fibrosis can be assessed by cardiovascular magnetic resonance (CMR) T1 mapping. We hypothesized that coronary microvascular disease is associated with diffuse myocardial fibrosis. METHODS: Women with angina, a clinically indicated coronary angiogram with <50 % stenosis and no diabetes were included. CFVR was measured using dipyridamole (0.84 mg/kg) and MBFR using adenosine (0.84 mg/kg). Focal fibrosis was assessed by 1.5 T CMR late gadolinium enhancement (0.1 mmol/kg) and diffuse myocardial fibrosis by T1 mapping using a modified Look-Locker pulse sequence measuring T1 and extracellular volume fraction (ECV). RESULTS: CFVR and CMR were performed in 64 women, mean (SD) age 62.5 (8.3) years. MBFR was performed in a subgroup of 54 (84 %) of these women. Mean native T1 was 1023 (86) and ECV (%) was 33.7 (3.5); none had focal fibrosis. Median (IQR) CFVR was 2.3 (1.9; 2.7), 23 (36 %) had CFVR < 2 indicating coronary microvascular disease, and median MBFR was 2.7 (2.2; 3.0) and 19 (35 %) had a MBFR value below 2.5. No significant correlations were found between CFVR and ECV or native T1 (R 2 = 0.02; p = 0.27 and R 2 = 0.004; p = 0.61, respectively). There were also no correlations between MBFR and ECV or native T1 (R 2 = 0.1; p = 0.13 and R 2 = 0.004, p = 0.64, respectively). CFVR and MBFR were correlated to hypertension and heart rate. CONCLUSION: In women with angina and no obstructive coronary artery disease we found no association between measures of coronary microvascular disease and myocardial fibrosis, suggesting that myocardial ischemia induced by coronary microvascular disease does not elicit myocardial fibrosis in this population. The examined parameters seem to provide independent information about myocardial and coronary disease.
Assuntos
Angina Pectoris/diagnóstico por imagem , Doença da Artéria Coronariana/diagnóstico por imagem , Circulação Coronária , Vasos Coronários/diagnóstico por imagem , Ecocardiografia Doppler , Imagem Cinética por Ressonância Magnética , Microcirculação , Imagem de Perfusão do Miocárdio/métodos , Miocárdio/patologia , Tomografia por Emissão de Pósitrons , Idoso , Angina Pectoris/patologia , Angina Pectoris/fisiopatologia , Meios de Contraste/administração & dosagem , Angiografia Coronária , Doença da Artéria Coronariana/patologia , Doença da Artéria Coronariana/fisiopatologia , Vasos Coronários/fisiopatologia , Dinamarca , Feminino , Fibrose , Humanos , Pessoa de Meia-Idade , Compostos Organometálicos/administração & dosagem , Valor Preditivo dos Testes , Prognóstico , Fatores de Risco , Vasodilatadores/administração & dosagem , Saúde da MulherRESUMO
BACKGROUND: The systolic forward travelling compression wave (sFCW) and diastolic backward travelling decompression waves (dBEW) predominantly accelerate coronary blood flow. The effect of a coronary stenosis on the intensity of these waves in the distal vessel is unknown. We investigated the relationship between established physiological indices of hyperemic coronary flow and the intensity of the two major accelerative coronary waves identified by Coronary Wave Intensity analysis (CWIA). METHODOLOGY / PRINCIPAL FINDINGS: Simultaneous intracoronary pressure and velocity measurement was performed during adenosine induced hyperemia in 17 patients with pressure / Doppler flow wires positioned distal to the target lesion. CWI profiles were generated from this data. Fractional Flow Reserve (FFR) and Coronary Flow Velocity Reserve (CFVR) were calculated concurrently. The intensity of the dBEW was significantly correlated with FFR (R = -0.70, P = 0.003) and CFVR (R = -0.73, P = 0.001). The intensity of the sFCW was also significantly correlated with baseline FFR (R = 0.71, p = 0.002) and CFVR (R = 0.59, P = 0.01). Stenting of the target lesion resulted in a median 178% (interquartile range 55-280%) (P<0.0001) increase in sFCW intensity and a median 117% (interquartile range 27-509%) (P = 0.001) increase in dBEW intensity. The increase in accelerative wave intensity following PCI was proportionate to the baseline FFR and CFVR, such that stenting of lesions associated with the greatest flow limitation (lowest FFR and CFVR) resulted in the largest increases in wave intensity. CONCLUSIONS: Increasing ischemia severity is associated with proportionate reductions in cumulative intensity of both major accelerative coronary waves. Impaired diastolic microvascular decompression may represent a novel, important pathophysiologic mechanism driving the reduction in coronary blood flow in the setting of an epicardial stenosis.
Assuntos
Angina Pectoris/fisiopatologia , Angioplastia Coronária com Balão , Estenose Coronária/fisiopatologia , Vasos Coronários/fisiopatologia , Hiperemia/fisiopatologia , Adenosina , Idoso , Angina Pectoris/diagnóstico por imagem , Angina Pectoris/patologia , Angina Pectoris/cirurgia , Velocidade do Fluxo Sanguíneo , Circulação Coronária , Estenose Coronária/diagnóstico por imagem , Estenose Coronária/patologia , Estenose Coronária/cirurgia , Vasos Coronários/patologia , Ecocardiografia Doppler , Feminino , Reserva Fracionada de Fluxo Miocárdico , Humanos , Hiperemia/induzido quimicamente , Hiperemia/patologia , Hiperemia/cirurgia , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , StentsRESUMO
Coronary artery fistulas represent the most common hemodynamically significant congenital defect of the coronary arteries and the clinical presentation is mainly dependent on the severity of the left-to-right shunt. We describe a case of a 55-year-old man with history of chest pain and without history of previous significant chest wall trauma or any invasive cardiac procedures. A coronary multislice computed tomography showed two large coronary fistulas arising from the left anterior descending coronary artery and ending in an angiomatous plexus draining into the common pulmonary trunk. Coronary angiography confirmed the CT finding and showed a third fistulous communication arising from the sinus node artery. Although coronary fistulas are infrequent, they are becoming increasingly important because their management and treatment could prevent serious complications. The latest guidelines of the American College of Cardiology/American Heart Association indicate as Class I recommendation the percutaneous or surgical closure for large fistulas regardless of symptoms. In this manuscript, we provide a detailed review of the literature on this topic, focusing on the clinical management of these patients.
Assuntos
Angina Pectoris/cirurgia , Doença da Artéria Coronariana/cirurgia , Fístula/cirurgia , Artéria Pulmonar/cirurgia , Angina Pectoris/diagnóstico , Angina Pectoris/patologia , Angiografia Coronária/métodos , Doença da Artéria Coronariana/complicações , Fístula/etiologia , Hemodinâmica/fisiologia , Humanos , Masculino , Pessoa de Meia-Idade , Resultado do TratamentoRESUMO
There were examined 134 patients, in whom in the clinic in 2005-2014 yrs a coronary shunting operation was performed. In patients with the angina pectoris recurrence a reoperation is indicated. The data of repeated coronaroventriculography and shuntography were analyzed. Efficacy of the surgical and interventional methods application in the patients was proved.
Assuntos
Angina Pectoris/cirurgia , Ponte de Artéria Coronária/métodos , Adulto , Idoso , Angina Pectoris/diagnóstico por imagem , Angina Pectoris/patologia , Angiografia Coronária , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Recidiva , Reoperação , Fatores de Tempo , Resultado do TratamentoRESUMO
In clinical trial included 41 patient with clinic-instrumental dates, which said about myocardium dysfunction and system diseases of connecting fabric and displays of CCI I-III of functional class (FC). Including of complex metabolic drug Cocarnit in standard therapy of systemdiseases of connecting fabric was instrumental in more expressed clinical improvement of patientsclinical dates in 15 days of supervision: a weakness diminished on 66.67%, shortbreathing at the insignificant physical loading--on 23.81%, at the ordinary physical loading--on 47.62%, at the megascopic physical loading--on 19.05%, pain in area of heart--on 42.85%, there are interruptions in-process heart--on 28.57%, oedematousness of shins--on 57.14%, sense of numbness, burning, sensitiveness to cold of extremities--on 57.14%. Quantity of patients with III FC diminished on 5 (23.81%), in a control group--on 2 (10%). It implementation of test with the 6-minute walking more expressed increase of the overcame distance is set for the patients of basicgroup--on 15.46% as compared to a control group--on 7.01%. Cocarnit patients estimatedpositively; side effects with subsequent abolition of drug, were not. Laboratory indexes (AlAT, AsAT, bilirubin, kreatinine, haemoglobin) at the end of trial did not change considerably, that confirmed good bearableness of drug.
Assuntos
Angina Pectoris/tratamento farmacológico , Cardiomiopatias/tratamento farmacológico , Cardiotônicos/uso terapêutico , Tecido Conjuntivo/efeitos dos fármacos , Dispneia/tratamento farmacológico , Insuficiência Cardíaca/prevenção & controle , Hipestesia/tratamento farmacológico , Trifosfato de Adenosina/uso terapêutico , Adulto , Idoso , Alanina Transaminase/sangue , Angina Pectoris/sangue , Angina Pectoris/patologia , Angina Pectoris/fisiopatologia , Aspartato Aminotransferases/sangue , Bilirrubina/sangue , Cardiomiopatias/sangue , Cardiomiopatias/patologia , Cardiomiopatias/fisiopatologia , Estudos de Casos e Controles , Tecido Conjuntivo/patologia , Creatinina/sangue , Combinação de Medicamentos , Dispneia/sangue , Dispneia/patologia , Dispneia/fisiopatologia , Feminino , Glicina/uso terapêutico , Insuficiência Cardíaca/sangue , Insuficiência Cardíaca/patologia , Insuficiência Cardíaca/fisiopatologia , Hemoglobinas/metabolismo , Humanos , Hipestesia/sangue , Hipestesia/patologia , Hipestesia/fisiopatologia , Masculino , Pessoa de Meia-Idade , Miocárdio/metabolismo , Miocárdio/patologia , Niacinamida/uso terapêutico , Tiamina Pirofosfato/uso terapêutico , Vitamina B 12/uso terapêuticoAssuntos
Angina Pectoris/etiologia , Angina Pectoris/patologia , Técnicas de Imagem Cardíaca , Doença de Fabry/complicações , Doença de Fabry/patologia , Imageamento por Ressonância Magnética , Adulto , Angina Pectoris/fisiopatologia , Doença de Fabry/fisiopatologia , Feminino , Humanos , Microcirculação/fisiologiaRESUMO
AIM: The aim of this study was to determine the prognostic significance of interleukin 6 (IL-6) and vascular endothelial growth factor (VEGF) in patients with chronic coronary artery disease treated who underwent percutaneous coronary intervention with stent implantation, for assessing the risk of restenosis and the occurrence of de novo lesions. PATIENTS AND METHODS: 498 patients with stable angina were examined during 18 months. 50 patients with significant (> 70%) stenosis of one coronary artery, eligible for the implantation of one stent, were enrolled to the study. Il-6 and VEGF level was measured using ELISA immunoassays during the initial coronary angiography with simultaneous angioplasty and stent implantation and 4 weeks after stent implantation. Coronary angiography was carried out 8-12 months after stent implantation. RESULTS: Statistically significant increase in IL-6 (from 4.02 ± 4.40 to 10.90 ± 8.23) and VEGF (from 310.13 ± 50.90 to 392.32 ± 106.84) level was observed 4 weeks after stent implantation in the group with restenosis. CONCLUSIONS: Increased levels of IL-6 and VEGF in the peripheral blood of patients with chronic stable angina pectoris, measured 4 weeks after coronary angioplasty with stent implantation, may indicate an increased risk of angiographic restenosis and de novo coronary artery lesions.
Assuntos
Angina Estável/metabolismo , Doença da Artéria Coronariana/metabolismo , Vasos Coronários/metabolismo , Interleucina-6/metabolismo , Fator A de Crescimento do Endotélio Vascular/metabolismo , Angina Pectoris/metabolismo , Angina Pectoris/patologia , Angina Estável/patologia , Angioplastia Coronária com Balão/métodos , Angiografia Coronária/métodos , Doença da Artéria Coronariana/patologia , Vasos Coronários/patologia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Prognóstico , StentsRESUMO
A challenge of modern cardiovascular medicine is to find new, effective treatments for patients with refractory angina pectoris, a clinical condition characterized by severe angina despite optimal medical therapy. These patients are not candidates for surgical or percutaneous revascularization. Herein we review the most up-to-date information regarding the modern approach to the patient with refractory angina pectoris, from conventional medical management to new medications and shock wave therapy, focusing on the use of endothelial precursor cells (EPCs) in the treatment of this condition. Clinical limitations of the efficiency of conventional approaches justify the search for new therapeutic options. Regenerative medicine is considered the next step in the evolution of organ replacement therapy. It is driven largely by the same health needs as transplantation and replacement therapies, but it aims further than traditional approaches, such as cell-based therapy. Increasing knowledge of the role of circulating cells derived from bone marrow (EPCs) on cardiovascular homeostasis in physiologic and pathologic conditions has prompted the clinical use of these cells to relieve ischemia. The current state of therapeutic angiogenesis still leaves many questions unanswered. It is of paramount importance that the treatment is delivered safely. Direct intramyocardial and intracoronary administration has demonstrated acceptable safety profiles in early trials, and may represent a major advance over surgical thoracotomy. The combined efforts of bench and clinical researchers will ultimately answer the question of whether cell therapy is a suitable strategy for treatment of patients with refractory angina.
Assuntos
Acetanilidas/uso terapêutico , Angina Pectoris/terapia , Células Endoteliais/transplante , Ondas de Choque de Alta Energia/uso terapêutico , Piperazinas/uso terapêutico , Bloqueadores dos Canais de Sódio/uso terapêutico , Transplante de Células-Tronco , Acetanilidas/efeitos adversos , Angina Pectoris/diagnóstico , Angina Pectoris/patologia , Angina Pectoris/fisiopatologia , Animais , Humanos , Neovascularização Fisiológica , Piperazinas/efeitos adversos , Ranolazina , Regeneração , Bloqueadores dos Canais de Sódio/efeitos adversos , Transplante de Células-Tronco/efeitos adversos , Resultado do TratamentoAssuntos
Angina Pectoris/diagnóstico por imagem , Angiografia Coronária , Doença da Artéria Coronariana/diagnóstico por imagem , Exercício Físico , Fístula/diagnóstico por imagem , Doença Iatrogênica , Idoso , Angina Pectoris/patologia , Biópsia/efeitos adversos , Cardiomiopatia Dilatada/diagnóstico por imagem , Cardiomiopatia Dilatada/patologia , Doença da Artéria Coronariana/patologia , Diagnóstico Diferencial , Endocárdio/patologia , Feminino , Ventrículos do Coração/diagnóstico por imagem , Ventrículos do Coração/patologia , Humanos , Miocárdio/patologiaRESUMO
BACKGROUND: Thymic stromal lymphopoietin (TSLP) has been shown to be expressed in various inflammatory tissues, such as human atherosclerotic plaques. Many types of myeloid cells involved in atherosclerosis, including mast cells, lymphocytes, dendritic cells and monocytes/macrophages, present TSLP receptors (TSLPR). However, it is unknown whether platelets, which also play important roles in atherothrombosis, express TSLPR. METHODS AND RESULTS: We applied flow cytometry and western blotting to show that TSLPR was expressed on the surface of human platelets. Following the addition of TSLP to platelets, the expression of CD62P, CD63, PAC-1 and p-Akt as well as aggregation and ATP release were increased significantly. A TSLPR antibody and a PI3K (phosphatidylinositol 3-kinase) enzyme inhibitor (LY294002) significantly inhibited the platelet activation induced by TSLP. The expression of TSLPR, CD62P and CD63 and the increment of the expression of CD62P and CD63 induced by TSLP in the acute coronary syndrome (ACS) group were markedly higher than those in the control group and the stable angina pectoris (SAP) group. The expression and the increment of the expression of CD62P and CD63 induced by TSLP were positively correlated with the expression of TSLPR. CONCLUSION: Human platelets express functional TSLPR, which can be activated by TSLP to promote platelet activation. TSLP/TSLPR functions via activating the PI3K/AKT pathway, and this signalling pathway may be one of the mechanisms involved in thrombosis in ACS. In coronary disease patients, the determination of TSLPR in platelets may help to identify the risk of ACS.
Assuntos
Síndrome Coronariana Aguda/metabolismo , Plaquetas/metabolismo , Receptores de Citocinas/metabolismo , Síndrome Coronariana Aguda/patologia , Idoso , Angina Pectoris/metabolismo , Angina Pectoris/patologia , Cromonas/farmacologia , Citocinas/metabolismo , Inibidores Enzimáticos/farmacologia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Morfolinas/farmacologia , Selectina-P/metabolismo , Fosfatidilinositol 3-Quinases/metabolismo , Inibidores de Fosfoinositídeo-3 Quinase , Fosforilação/efeitos dos fármacos , Ativação Plaquetária/efeitos dos fármacos , Proteínas Proto-Oncogênicas c-akt/metabolismo , Transdução de Sinais/efeitos dos fármacos , Tetraspanina 30/metabolismo , Linfopoietina do Estroma do TimoRESUMO
BACKGROUND: Vascular progenitor cells (VPCs) are a heterogeneous population, containing a subpopulation co-expressing both endothelial and smooth muscle phenotypes. This study sought to determine whether the level of this subpopulation correlated with the coronary Gensini score. METHODS AND RESULTS: VPCs were cultivated in 50 patients undergoing coronary angiography. A subpopulation of VPCs expressed both endothelial (VE-cadherin [VE-Cad]) and smooth-muscle phenotypes (α-smooth muscle actin [α-SMA]). Correlations of the VE-Cad(low)α-SMA(+) VPC level and adhesion molecule expression by VPCs with the Gensini score were investigated. The association between the amount of this subpopulation and the development of intimal hyperplasia (IH) was also estimated in a vascular injury animal model. Both the number of VE-Cad(low)α-SMA(+) VPCs (P = 0.002) and the expression level of intracellular adhesion molecule (ICAM)-1 by VPCs (P = 0.008) correlated with the Gensini score. However, only the number of VE-Cad(low)α-SMA(+) VPCs (P = 0.004) and the blood level of low-density lipoprotein cholesterol (P = 0.016) were parameters independently associated with the Gensini score in multivariate analysis. Furthermore, in an animal model of injecting VPCs into SCID mice after femoral artery wire injury, a higher number of VE-Cad(low)α-SMA(+) VPCs correlated with greater IH (r = 0.69, P<0.0001). CONCLUSIONS: The level of VE-Cad(low)α-SMA(+) VPCs was associated with the severity of coronary atherosclerosis as quantified by the Gensini score. Manipulating this subpopulation may provide a way of attenuating atherosclerosis in the future.
Assuntos
Actinas/metabolismo , Antígenos CD/metabolismo , Caderinas/metabolismo , Doença da Artéria Coronariana/metabolismo , Vasos Coronários/metabolismo , Células-Tronco Hematopoéticas/metabolismo , Índice de Gravidade de Doença , Idoso , Angina Pectoris/metabolismo , Angina Pectoris/patologia , Animais , Adesão Celular/fisiologia , Células Cultivadas , Doença da Artéria Coronariana/patologia , Vasos Coronários/citologia , Células Endoteliais/citologia , Feminino , Transplante de Células-Tronco Hematopoéticas , Células-Tronco Hematopoéticas/citologia , Humanos , Masculino , Camundongos , Camundongos SCID , Pessoa de Meia-Idade , Músculo Liso Vascular/citologiaRESUMO
BACKGROUND: Experimental studies demonstrate that granulocyte colony stimulating factor (G-CSF) promotes neovascularisation and confers cardioprotection. OBJECTIVE: To assess the efficacy of repeated low dose G-CSF plus exercise on myocardial ischaemia in patients with severe chronic ischaemic heart disease. METHODS: 18 patients with Canadian Cardiovascular Society class III-IV angina completed a randomised, double blind, crossover study of dose adjusted G-CSF versus placebo. Exercise was commenced 6 weeks prior and continued for the duration of the study. G-CSF or placebo was administered daily for 5 consecutive days at fortnightly intervals for three cycles, followed by crossover after 6 weeks. Primary outcome was myocardial perfusion by cardiac magnetic resonance imaging (MRI). Secondary outcomes were: Seattle Angina and Utility Based Quality of Life Heart Questionnaire (SAQ/UBQ-H), Exercise Stress Test (EST) and quantification of endothelial progenitor cells (EPC) by flow cytometry and angiogenic cytokines by immunoassay. RESULTS: Compared with placebo, G-CSF had no effect on myocardial ischaemia by cardiac MRI, EST or SAQ/UBQ-H, despite effective EPC mobilisation (peak fold increase: CD34+ =19, CD34+ CD133+ = 37, CD34+ vascular endothelial growth factor receptor 2 (VEGFR-2)+ = 5, CD34+ CD133+ VEGFR-2+ = 3; all p<0.05 vs. placebo). Plasma levels of stromal cell derived factor 1, angiopoietin 1, interleukin 8 and tumour necrosis factor α decreased after a symptom limited EST while vascular endothelial growth factor and platelet derived growth factor remained unchanged. All cytokines were unchanged following G-CSF. Seven troponin I positive events occurred with G-CSF compared with three with placebo (p=0.289). High sensitivity C reactive protein and N terminal prohormone brain natriuretic peptide increased with G-CSF (both p<0.01 vs. placebo). CONCLUSION: In patients with chronic ischaemic heart disease, G-CSF mobilises EPCs but does not improve myocardial perfusion or angina. G-CSF increases plasma levels of adverse prognostic cardiac biomarkers. Clinical trial registration information Australian New Zealand Clinical Trials Registry: http://www.anzctr.org.au. Unique identifier: ACTRN012607000354482.
Assuntos
Angina Pectoris/tratamento farmacológico , Vasos Coronários/patologia , Fator Estimulador de Colônias de Granulócitos/administração & dosagem , Neovascularização Fisiológica/efeitos dos fármacos , Idoso , Angina Pectoris/patologia , Doença Crônica , Vasos Coronários/efeitos dos fármacos , Estudos Cross-Over , Relação Dose-Resposta a Droga , Método Duplo-Cego , Teste de Esforço , Feminino , Citometria de Fluxo , Seguimentos , Fator Estimulador de Colônias de Granulócitos/uso terapêutico , Humanos , Imunoensaio , Imagem Cinética por Ressonância Magnética , Masculino , Pessoa de Meia-Idade , Neovascularização Fisiológica/fisiologia , Estudos Prospectivos , Qualidade de Vida , Inquéritos e Questionários , Resultado do TratamentoRESUMO
IgE has a key role in the pathogenesis of allergic responses through its ability to activate mast cells via the receptor FcεR1. In addition to mast cells, many cell types implicated in atherogenesis express FcεR1, but whether IgE has a role in this disease has not been determined. Here, we demonstrate that serum IgE levels are elevated in patients with myocardial infarction or unstable angina pectoris. We found that IgE and the FcεR1 subunit FcεR1α were present in human atherosclerotic lesions and that they localized particularly to macrophage-rich areas. In mice, absence of FcεR1α reduced inflammation and apoptosis in atherosclerotic plaques and reduced the burden of disease. In cultured macrophages, the presence of TLR4 was required for FcεR1 activity. IgE stimulated the interaction between FcεR1 and TLR4, thereby inducing macrophage signal transduction, inflammatory molecule expression, and apoptosis. These IgE activities were reduced in the absence of FcεR1 or TLR4. Furthermore, IgE activated macrophages by enhancing Na+/H+ exchanger 1 (NHE1) activity. Inactivation of NHE1 blocked IgE-induced macrophage production of inflammatory molecules and apoptosis. Cultured human aortic SMCs (HuSMCs) and ECs also exhibited IgE-induced signal transduction, cytokine expression, and apoptosis. In human atherosclerotic lesions, SMCs and ECs colocalized with IgE and TUNEL staining. This study reveals what we believe to be several previously unrecognized IgE activities that affect arterial cell biology and likely other IgE-associated pathologies in human diseases.
Assuntos
Apolipoproteínas E/metabolismo , Apoptose/fisiologia , Aterosclerose/fisiopatologia , Citocinas/metabolismo , Imunoglobulina E/metabolismo , Angina Pectoris/sangue , Angina Pectoris/imunologia , Angina Pectoris/patologia , Animais , Apolipoproteínas E/genética , Aterosclerose/patologia , Células Cultivadas , China , Gorduras na Dieta/efeitos adversos , Humanos , Macrófagos/citologia , Macrófagos/fisiologia , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Knockout , Pessoa de Meia-Idade , Infarto do Miocárdio/sangue , Infarto do Miocárdio/imunologia , Infarto do Miocárdio/patologia , Placa Aterosclerótica/química , Placa Aterosclerótica/imunologia , Placa Aterosclerótica/patologia , Receptores de IgE/genética , Receptores de IgE/metabolismo , Trocadores de Sódio-Hidrogênio/genética , Trocadores de Sódio-Hidrogênio/metabolismo , Receptor 4 Toll-Like/genética , Receptor 4 Toll-Like/metabolismoAssuntos
Angina Pectoris/cirurgia , Antígenos CD34/metabolismo , Circulação Coronária , Células Endoteliais/transplante , Transplante de Células-Tronco Hematopoéticas , Microcirculação , Isquemia Miocárdica/cirurgia , Angina Pectoris/etiologia , Angina Pectoris/mortalidade , Angina Pectoris/patologia , Angina Pectoris/fisiopatologia , Animais , Biomarcadores/metabolismo , Células Endoteliais/imunologia , Tolerância ao Exercício , Transplante de Células-Tronco Hematopoéticas/efeitos adversos , Humanos , Isquemia Miocárdica/complicações , Isquemia Miocárdica/mortalidade , Isquemia Miocárdica/patologia , Isquemia Miocárdica/fisiopatologia , Miocárdio/patologia , Neovascularização Fisiológica , Seleção de Pacientes , Regeneração , Medição de Risco , Fatores de Risco , Fatores de Tempo , Transplante Autólogo , Resultado do TratamentoRESUMO
RATIONALE: A growing number of patients with coronary disease have refractory angina. Preclinical and early-phase clinical data suggest that intramyocardial injection of autologous CD34+ cells can improve myocardial perfusion and function. OBJECTIVE: Evaluate the safety and bioactivity of intramyocardial injections of autologous CD34+ cells in patients with refractory angina who have exhausted all other treatment options. METHODS AND RESULTS: In this prospective, double-blind, randomized, phase II study (ClinicalTrials.gov identifier: NCT00300053), 167 patients with refractory angina received 1 of 2 doses (1×10(5) or 5×10(5) cells/kg) of mobilized autologous CD34+ cells or an equal volume of diluent (placebo). Treatment was distributed into 10 sites of ischemic, viable myocardium with a NOGA mapping injection catheter. The primary outcome measure was weekly angina frequency 6 months after treatment. Weekly angina frequency was significantly lower in the low-dose group than in placebo-treated patients at both 6 months (6.8±1.1 versus 10.9±1.2, P=0.020) and 12 months (6.3±1.2 versus 11.0±1.2, P=0.035); measurements in the high-dose group were also lower, but not significantly. Similarly, improvement in exercise tolerance was significantly greater in low-dose patients than in placebo-treated patients (6 months: 139±151 versus 69±122 seconds, P=0.014; 12 months: 140±171 versus 58±146 seconds, P=0.017) and greater, but not significantly, in the high-dose group. During cell mobilization and collection, 4.6% of patients had cardiac enzyme elevations consistent with non-ST segment elevation myocardial infarction. Mortality at 12 months was 5.4% in the placebo-treatment group with no deaths among cell-treated patients. CONCLUSIONS: Patients with refractory angina who received intramyocardial injections of autologous CD34+ cells (10(5) cells/kg) experienced significant improvements in angina frequency and exercise tolerance. The cell-mobilization and -collection procedures were associated with cardiac enzyme elevations, which will be addressed in future studies.